The Form 4 filing, an SEC report of an insider's stock trades, was filed on Nov. 19, 2026. It covers trades made two days earlier, on Nov. 17, by Neurocrine Biosciences (NBIX) director Gary A. Lyons.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-17 |
| Date of Latest Transaction | 2026-11-17 |
| Buy/Sell | sell |
| Transaction Count | 4 |
| Shares Transacted | 15,000 |
| Price | $164.87 |
| Total Transaction Value | $2,473,030.01 |
| Insider | |
| Ticker Symbol | NBIX |
| Company | NEUROCRINE BIOSCIENCES INC |
| Insider Name | LYONS GARY A |
| Insider Title | Director |
| Sector - Industry | Healthcare - Drug Manufacturers - Specialty & Generic |
| Holdings | |
| Total Shares Owned After Transaction | 122,141 |
| Position Size Change | 10.94% |
| Filing | |
| Filing Date | 2026-11-19 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were sales of company shares, reported with SEC transaction code S. The report covers four sale transactions by one insider, Gary A. Lyons. They appear in a single filing.
What was the average price of the transaction?
The average sale price was $164.87 per share across the four transactions. Separate prices for each sale are not available in the transaction details.
How did this transaction affect the insider's holdings?
Gary A. Lyons sold 15,000 shares and reported owning 122,141 shares afterward. The sales represented 10.94% of the shares he owned before the sales.
What's the total transaction value?
The total value was $2,473,030.01 for all four sales combined.
Are there any special circumstances around this transaction?
The filing information identifies a reference to a Rule 10b5-1 trading plan. These plans set stock-trading instructions in advance. The available details do not confirm which of the four sales the reference covers. Footnote text and plan terms were not available, so the plan's start date and trading schedule remain unknown.
For research purposes only; not investment advice.